The SARS-CoV ferret model in an infection-challenge study

Yong Kyu Chu, Georgia D. Ali, Fuli Jia, Qianjun Li, David Kelvin, Ronald C. Couch, Kevin S. Harrod, Julie A. Hutt, Cheryl Cameron, Susan R. Weiss, Colleen Jonsson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 103 TCID50 SARS-CoV showed higher body temperature (2-6 d.p.i.), sneezing (5-10 d.p.i.), lesions (5-7 d.p.i.) and decreased WBC/lymphocytes (2-5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 103 TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.

Original languageEnglish (US)
Pages (from-to)151-163
Number of pages13
JournalVirology
Volume374
Issue number1
DOIs
StatePublished - Apr 25 2008
Externally publishedYes

Fingerprint

Severe Acute Respiratory Syndrome
Ferrets
Coronavirus
Infection
Neutralizing Antibodies
Sneezing
Body Temperature
Animal Models
Lymphocytes
Viruses
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Virology

Cite this

Chu, Y. K., Ali, G. D., Jia, F., Li, Q., Kelvin, D., Couch, R. C., ... Jonsson, C. (2008). The SARS-CoV ferret model in an infection-challenge study. Virology, 374(1), 151-163. https://doi.org/10.1016/j.virol.2007.12.032

The SARS-CoV ferret model in an infection-challenge study. / Chu, Yong Kyu; Ali, Georgia D.; Jia, Fuli; Li, Qianjun; Kelvin, David; Couch, Ronald C.; Harrod, Kevin S.; Hutt, Julie A.; Cameron, Cheryl; Weiss, Susan R.; Jonsson, Colleen.

In: Virology, Vol. 374, No. 1, 25.04.2008, p. 151-163.

Research output: Contribution to journalArticle

Chu, YK, Ali, GD, Jia, F, Li, Q, Kelvin, D, Couch, RC, Harrod, KS, Hutt, JA, Cameron, C, Weiss, SR & Jonsson, C 2008, 'The SARS-CoV ferret model in an infection-challenge study', Virology, vol. 374, no. 1, pp. 151-163. https://doi.org/10.1016/j.virol.2007.12.032
Chu YK, Ali GD, Jia F, Li Q, Kelvin D, Couch RC et al. The SARS-CoV ferret model in an infection-challenge study. Virology. 2008 Apr 25;374(1):151-163. https://doi.org/10.1016/j.virol.2007.12.032
Chu, Yong Kyu ; Ali, Georgia D. ; Jia, Fuli ; Li, Qianjun ; Kelvin, David ; Couch, Ronald C. ; Harrod, Kevin S. ; Hutt, Julie A. ; Cameron, Cheryl ; Weiss, Susan R. ; Jonsson, Colleen. / The SARS-CoV ferret model in an infection-challenge study. In: Virology. 2008 ; Vol. 374, No. 1. pp. 151-163.
@article{eeb2f564240c415185ca2c85f730242a,
title = "The SARS-CoV ferret model in an infection-challenge study",
abstract = "Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 103 TCID50 SARS-CoV showed higher body temperature (2-6 d.p.i.), sneezing (5-10 d.p.i.), lesions (5-7 d.p.i.) and decreased WBC/lymphocytes (2-5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 103 TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.",
author = "Chu, {Yong Kyu} and Ali, {Georgia D.} and Fuli Jia and Qianjun Li and David Kelvin and Couch, {Ronald C.} and Harrod, {Kevin S.} and Hutt, {Julie A.} and Cheryl Cameron and Weiss, {Susan R.} and Colleen Jonsson",
year = "2008",
month = "4",
day = "25",
doi = "10.1016/j.virol.2007.12.032",
language = "English (US)",
volume = "374",
pages = "151--163",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The SARS-CoV ferret model in an infection-challenge study

AU - Chu, Yong Kyu

AU - Ali, Georgia D.

AU - Jia, Fuli

AU - Li, Qianjun

AU - Kelvin, David

AU - Couch, Ronald C.

AU - Harrod, Kevin S.

AU - Hutt, Julie A.

AU - Cameron, Cheryl

AU - Weiss, Susan R.

AU - Jonsson, Colleen

PY - 2008/4/25

Y1 - 2008/4/25

N2 - Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 103 TCID50 SARS-CoV showed higher body temperature (2-6 d.p.i.), sneezing (5-10 d.p.i.), lesions (5-7 d.p.i.) and decreased WBC/lymphocytes (2-5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 103 TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.

AB - Phase I human clinical studies involving therapeutics for emerging and biodefense pathogens with low incidence, such as the severe acute respiratory syndrome coronavirus (SARS-CoV), requires at a minimum preclinical evaluation of efficacy in two well-characterized and robust animal models. Thus, a ferret SARS-CoV model was evaluated over a period of 58 days following extensive optimization and characterization of the model in order to validate clinical, histopathological, virological and immunological endpoints. Ferrets that were infected intranasally with 103 TCID50 SARS-CoV showed higher body temperature (2-6 d.p.i.), sneezing (5-10 d.p.i.), lesions (5-7 d.p.i.) and decreased WBC/lymphocytes (2-5 d.p.i.). SARS-CoV was detected up to 7 d.p.i. in various tissues and excreta, while neutralizing antibody titers rose at 7 d.p.i. and peaked at 14 d.p.i. At 29 d.p.i., one group was challenged with 103 TCID50 SARS-CoV, and an anamnestic response in neutralizing antibodies was evident with no detectable virus. This study supports the validity of the ferret model for use in evaluating efficacy of potential therapeutics to treat SARS.

UR - http://www.scopus.com/inward/record.url?scp=41649107278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649107278&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2007.12.032

DO - 10.1016/j.virol.2007.12.032

M3 - Article

VL - 374

SP - 151

EP - 163

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -